LMN-101 is under clinical development by Lumen Bioscience and currently in Phase I for Traveler’s Diarrhea. According to GlobalData, Phase I drugs for Traveler’s Diarrhea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LMN-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LMN-101 overview

LMN-101 is under development for the treatment of Campylobacter jejuni infections and traveler’s diarrhea which is caused by the bacterial pathogens Campylobacter jejuni and enterotoxigenic E. coli. It is administered through oral route in the form of capsule. It acts by targeting flagellin filament protein. The drug candidate is being developed based on Spirulina technology platform.

Lumen Bioscience overview

Lumen Bioscience is a developer of oral antibody therapeutics. Lumen Bioscience is headquartered in Seattle, Washington, the US.

For a complete picture of LMN-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.